{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:32:22Z","timestamp":1790965942090,"version":"4.1.0"},"reference-count":308,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Food and Chemical Toxicology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.fct.2019.110822","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T19:05:01Z","timestamp":1568660701000},"page":"110822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Phosphodiesterase inhibitors say NO to Alzheimer's disease"],"prefix":"10.1016","volume":"134","author":[{"given":"Seyed Mohammad","family":"Nabavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Talarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Listos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Fazel","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-8961","authenticated-orcid":false,"given":"Kasi Pandima","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Roberto de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5125-3791","authenticated-orcid":false,"given":"Devesh","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Arg\u00fcelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Mehrzadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"D'onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkay Erdogan","family":"Orhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8656-6838","authenticated-orcid":false,"given":"Antoni","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5488-5217","authenticated-orcid":false,"given":"Suowen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3957-3300","authenticated-orcid":false,"given":"Saeedeh","family":"Momtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-6521","authenticated-orcid":false,"given":"Mohammad Hosein","family":"Farzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0092-8674(00)81904-2","article-title":"Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory","volume":"88","author":"Abel","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.fct.2019.110822_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cellsig.2017.07.018","article-title":"Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families","volume":"39","author":"Abusnina","year":"2017","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib3","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/odi.12275","article-title":"Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets","volume":"21","author":"Ahmad","year":"2015","journal-title":"Oral Dis."},{"key":"10.1016\/j.fct.2019.110822_bib4","first-page":"1","article-title":"Effects of rolipram and zaprinast on learning and memory in the Morris water maze and radial arm maze tests in naive mice","volume":"64","author":"Akar","year":"2014","journal-title":"Drug Res."},{"issue":"02","key":"10.1016\/j.fct.2019.110822_bib5","first-page":"86","article-title":"Effects of rolipram and zaprinast on learning and memory in the Morris water maze and radial arm maze tests in naive mice","volume":"65","author":"Akar","year":"2015","journal-title":"Drug Res."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/13685538.2017.1367922","article-title":"Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia","volume":"21","author":"Amano","year":"2018","journal-title":"Aging Male"},{"issue":"21","key":"10.1016\/j.fct.2019.110822_bib7","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/heartjnl-2015-309223","article-title":"Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality","volume":"102","author":"Anderson","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.fct.2019.110822_bib8","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors\u2013pharmacology and clinical applications 20 years after sildenafil discovery","author":"Andersson","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.fct.2019.110822_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0304-3940(01)02269-8","article-title":"The anti-emetic action of the neurokinin1 receptor antagonist CP-99,994 does not require the presence of the area postrema in the dog","volume":"314","author":"Andrews","year":"2001","journal-title":"Neurosci. Lett."},{"issue":"11","key":"10.1016\/j.fct.2019.110822_bib10","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1111\/jth.12711","article-title":"Role of inorganic nitrate and nitrite in driving nitric oxide\u2013cGMP\u2010mediated inhibition of platelet aggregation in vitro and in vivo","volume":"12","author":"Apostoli","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"s1","key":"10.1016\/j.fct.2019.110822_bib11","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.3233\/JAD-2010-091249","article-title":"Caffeine and coffee as therapeutics against Alzheimer's disease","volume":"20","author":"Arendash","year":"2010","journal-title":"J. Alzheimer's Dis."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0006-291X(63)90566-7","article-title":"Isolation of adenosine 3\u2032, 5\u2032-monophosphate and guanosine 3\u2032, 5\u2032-monophosphate from rat urine","volume":"11","author":"Ashman","year":"1963","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.fct.2019.110822_bib13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0006-2952(96)00053-6","article-title":"Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H] rolipram binding","volume":"51","author":"Bamette","year":"1996","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib14","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0022-3565(25)09664-8","article-title":"Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site","volume":"273","author":"Barnette","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(24)37221-0","article-title":"Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitroanti-inflammatory actions","volume":"284","author":"Barnette","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"58","key":"10.1016\/j.fct.2019.110822_bib16","doi-asserted-by":"crossref","first-page":"99179","DOI":"10.18632\/oncotarget.21837","article-title":"Phosphodiesterase type 5 and cancers: progress and challenges","volume":"8","author":"Barone","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13195-018-0352-4","article-title":"Amyloid beta-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition","volume":"10","author":"Bartolome","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib18","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington's disease models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1152\/physrev.1995.75.4.725","article-title":"Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms","volume":"75","author":"Beavo","year":"1995","journal-title":"Physiol. Rev."},{"issue":"21","key":"10.1016\/j.fct.2019.110822_bib20","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1016\/S0021-9258(18)62703-6","article-title":"Hydrolysis of cyclic guanosine and adenosine 3', 5'-monophosphates by rat and bovine tissues","volume":"245","author":"Beavo","year":"1970","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0026-895X(25)09714-7","article-title":"Multiple cyclic nucleotide phosphodiesterases","volume":"46","author":"Beavo","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.fct.2019.110822_bib22","series-title":"Cyclic Nucleotide Phosphodiesterases in Health and Disease","author":"Beavo","year":"2006"},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.fct.2019.110822_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejphar.2016.06.034","article-title":"Challenges for the pharmacological treatment of neurological and psychiatric disorders: implications of the Ca2+\/cAMP intracellular signalling interaction","volume":"788","author":"Bergantin","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.fct.2019.110822_bib26","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1073\/pnas.94.13.7041","article-title":"Involvement of hippocampal cAMP\/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats","volume":"94","author":"Bernabeu","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.fct.2019.110822_bib27","series-title":"Nimodipine for Primary Degenerative, Mixed and Vascular Dementia","author":"Birks","year":"2002"},{"issue":"S1","key":"10.1016\/j.fct.2019.110822_bib28","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ijir.3901208","article-title":"Potency, selectivity, and consequences of nonselectivity of PDE inhibition","volume":"16","author":"Bischoff","year":"2004","journal-title":"Int. J. Impot. Res."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bbr.2011.02.016","article-title":"Sildenafil, a selective phosphodiesterase type 5 inhibitor, enhances memory reconsolidation of an inhibitory avoidance task in mice","volume":"220","author":"Boccia","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0898-6568(94)90018-3","article-title":"Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes","volume":"6","author":"Bolger","year":"1994","journal-title":"Cell. Signal"},{"key":"10.1016\/j.fct.2019.110822_bib31","series-title":"Phosphodiesterases: CNS Functions and Diseases","first-page":"63","article-title":"The PDE4 camp-specific phosphodiesterases: targets for drugs with antidepressant and memory-enhancing action","author":"Bolger","year":"2017"},{"key":"10.1016\/j.fct.2019.110822_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuropharm.2015.04.008","article-title":"Object memory enhancement by combining sub-efficacious doses of specific phosphodiesterase inhibitors","volume":"95","author":"Bollen","year":"2015","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1464-410X.1996.10220.x","article-title":"Sildenafil, a novel effective oral therapy for male erectile dysfunction","volume":"78","author":"Boolell","year":"1996","journal-title":"Br. J. Urol."},{"issue":"S1","key":"10.1016\/j.fct.2019.110822_bib34","first-page":"S252","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"BoswellSmith","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"18","key":"10.1016\/j.fct.2019.110822_bib35","doi-asserted-by":"crossref","first-page":"10518","DOI":"10.1073\/pnas.1834280100","article-title":"A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4","volume":"100","author":"Bourtchouladze","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib36","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/j.1476-5381.2011.01524.x","article-title":"GEBR\u20107b, a novel PDE4D selective inhibitor that improves memory in rodents at non\u2010emetic doses","volume":"164","author":"Bruno","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib37","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.neuropharm.2006.06.018","article-title":"Neuroanatomical and pharmacological assessment of Fos expression induced in the rat brain by the phosphodiesterase-4 inhibitor 6-(4-pyridylmethyl)-8-(3-nitrophenyl) quinoline","volume":"51","author":"Bureau","year":"2006","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.urology.2005.11.045","article-title":"Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism","volume":"67","author":"Burnett","year":"2006","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.fct.2019.110822_bib39","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0021-9258(18)60316-3","article-title":"Adenosine 3', 5'-phosphate in biological materials","volume":"237","author":"Butcher","year":"1962","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.fct.2019.110822_bib40","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1152\/jn.1988.59.2.358","article-title":"Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides","volume":"59","author":"Carpenter","year":"1988","journal-title":"J. Neurophysiol."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/ijcp.12305","article-title":"Tadalafil\u2013a therapeutic option in the management of BPH\u2010LUTS","volume":"68","author":"Carson","year":"2014","journal-title":"Int. J. Clin. Pract."},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib43","doi-asserted-by":"crossref","first-page":"H1513","DOI":"10.1152\/ajpheart.00529.2001","article-title":"Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure","volume":"284","author":"Chen","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib44","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2967\/jnumed.115.171454","article-title":"Preclinical evaluation of 18F-PF-05270430, a novel PET radioligand for the phosphodiesterase 2A enzyme","volume":"57","author":"Chen","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00213-010-1943-3","article-title":"Inhibition of phosphodiesterase-4 reverses memory deficits produced by A\u03b225\u201335 or A\u03b21\u201340 peptide in rats","volume":"212","author":"Cheng","year":"2010","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/(SICI)1096-9861(19990503)407:2<287::AID-CNE9>3.0.CO;2-R","article-title":"Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect","volume":"407","author":"Cherry","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.fct.2019.110822_bib47","first-page":"341","article-title":"Udenafil for the treatment of erectile dysfunction","volume":"10","author":"Cho","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib48","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.foodchem.2012.04.148","article-title":"Crude caffeine reduces memory impairment and amyloid \u03b21\u201342 levels in an Alzheimer's mouse model","volume":"135","author":"Chu","year":"2012","journal-title":"Food Chem."},{"issue":"21","key":"10.1016\/j.fct.2019.110822_bib49","doi-asserted-by":"crossref","first-page":"9055","DOI":"10.1021\/jm3009635","article-title":"Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors","volume":"55","author":"Claffey","year":"2012","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1210\/edrv-16-3-370","article-title":"Recent progress in understanding the hormonal regulation of phosphodiesterases","volume":"16","author":"Conti","year":"1995","journal-title":"Endocr. Rev."},{"issue":"1\u20132","key":"10.1016\/j.fct.2019.110822_bib51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0303-7207(01)00686-4","article-title":"Role of cyclic nucleotide signaling in oocyte maturation","volume":"187","author":"Conti","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"issue":"20","key":"10.1016\/j.fct.2019.110822_bib52","doi-asserted-by":"crossref","first-page":"13729","DOI":"10.1074\/jbc.274.20.13729","article-title":"Cyclic GMP phosphodiesterase-5: target of sildenafil","volume":"274","author":"Corbin","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib53","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1046\/j.1432-1327.2000.01297.x","article-title":"Phosphorylation of phosphodiesterase\u20105 by cyclic nucleotide\u2010dependent protein kinase alters its catalytic and allosteric cGMP\u2010binding activities","volume":"267","author":"Corbin","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14740338.2016.1130126","article-title":"The safety and efficacy of avanafil, a new 2nd generation PDE5i: comprehensive review and meta-analysis","volume":"15","author":"Corona","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"11","key":"10.1016\/j.fct.2019.110822_bib55","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J. Histochem. Cytochem."},{"issue":"S1","key":"10.1016\/j.fct.2019.110822_bib56","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/sj.ijir.3901212","article-title":"Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5","volume":"16","author":"Cote","year":"2004","journal-title":"Int. J. Impot. Res."},{"key":"10.1016\/j.fct.2019.110822_bib57","first-page":"195","article-title":"Alzheimer's disease drug development pipeline","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib58","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/nar\/gkr767","article-title":"Structural insights to the metal specificity of an archaeal member of the LigD 3\u2032-phosphoesterase DNA repair enzyme family","volume":"40","author":"Das","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.fct.2019.110822_bib59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"21","key":"10.1016\/j.fct.2019.110822_bib60","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1021\/jm030056e","article-title":"The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5, 6, 11, 11a-tetrahydro-1 H-imidazo [1 \u2018, 5 \u2018: 1, 6] pyrido [3, 4-b] indole-1, 3 (2 H)-dione analogues","volume":"46","author":"Daugan","year":"2003","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib61","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0193-953X(18)30318-6","article-title":"The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach","volume":"14","author":"Davidson","year":"1991","journal-title":"Psychiatr. Clin. N. Am."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib62","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.coph.2011.09.015","article-title":"From PDE3B to the regulation of energy homeostasis","volume":"11","author":"Degerman","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"issue":"22","key":"10.1016\/j.fct.2019.110822_bib63","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.1016\/j.bmcl.2012.09.028","article-title":"Future directions in phosphodiesterase drug discovery","volume":"22","author":"DeNinno","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib64","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.bmcl.2009.03.024","article-title":"The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents","volume":"19","author":"DeNinno","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0091-3057(87)90552-1","article-title":"Vinpocetine enhances retrieval of a step-through passive avoidance response in rats","volume":"26","author":"DeNoble","year":"1987","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"12","key":"10.1016\/j.fct.2019.110822_bib66","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/j.bbadis.2014.08.016","article-title":"Investigation of cAMP microdomains as a path to novel cancer diagnostics","volume":"1842","author":"Desman","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib67","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2337\/diacare.25.8.1336","article-title":"Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes","volume":"25","author":"Desouza","year":"2002","journal-title":"Diabetes Care"},{"issue":"2\u20133","key":"10.1016\/j.fct.2019.110822_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12035-010-8104-x","article-title":"Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease","volume":"41","author":"Domek-\u0141opaci\u0144ska","year":"2010","journal-title":"Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib69","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1021\/acs.jmedchem.7b00302","article-title":"Discovery of selective phosphodiesterase 1 inhibitors with memory enhancing properties","volume":"60","author":"Dyck","year":"2017","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib70","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/2141-9248.183943","article-title":"The wonders of phosphodiesterase-5 inhibitors: a majestic history","volume":"6","author":"Elhwuegi","year":"2016","journal-title":"Ann. Med. Health Sci. Res."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/07853890802441169","article-title":"Phosphodiesterase genes and antidepressant treatment response: a review","volume":"41","author":"Esposito","year":"2009","journal-title":"Ann. Med."},{"key":"10.1016\/j.fct.2019.110822_bib72","first-page":"1","article-title":"Early preclinical changes in hippocampal CREB-binding protein expression in a mouse model of familial Alzheimer's disease","author":"Ettcheto","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"7","key":"10.1016\/j.fct.2019.110822_bib73","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1073\/pnas.97.7.3702","article-title":"Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A","volume":"97","author":"Fawcett","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib74","first-page":"8","article-title":"PDE4-mediated cAMP signalling","volume":"5","author":"Fertig","year":"2018","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.fct.2019.110822_bib75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejmech.2012.12.009","article-title":"Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease","volume":"60","author":"Fiorito","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib76","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cbpb.2005.04.012","article-title":"Species-and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels","volume":"142","author":"Fischmeister","year":"2005","journal-title":"Comp. Biochem. Physiol. Mol. Integr. Physiol."},{"issue":"25","key":"10.1016\/j.fct.2019.110822_bib77","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","article-title":"Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase","volume":"273","author":"Fisher","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"49","key":"10.1016\/j.fct.2019.110822_bib78","doi-asserted-by":"crossref","first-page":"47581","DOI":"10.1074\/jbc.M206088200","article-title":"Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity","volume":"277","author":"Francis","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.fct.2019.110822_bib79","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-642-13443-2_4","article-title":"Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds","author":"Francis","year":"2011","journal-title":"in Methylxanthines"},{"key":"10.1016\/j.fct.2019.110822_bib80","series-title":"Phosphodiesterases as Drug Targets","first-page":"47","article-title":"Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action","author":"Francis","year":"2011"},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib81","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3233\/JAD-2012-121537","article-title":"Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes","volume":"33","author":"Froestl","year":"2013","journal-title":"J. Alzheimer's Dis."},{"issue":"26","key":"10.1016\/j.fct.2019.110822_bib82","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.fct.2019.110822_bib83","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1016\/j.bmcl.2010.09.087","article-title":"Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment","volume":"20","author":"Gallant","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1574-6968.2001.tb10814.x","article-title":"Novel domains of the prokaryotic two-component signal transduction systems","volume":"203","author":"Galperin","year":"2001","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.fct.2019.110822_bib85","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuropharm.2012.06.052","article-title":"Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD","volume":"64","author":"Garcia-Barroso","year":"2013","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.fct.2019.110822_bib86","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/cn3000907","article-title":"Phosphodiesterases as therapeutic targets for Alzheimer's disease","volume":"3","author":"Garc\u00eda-Osta","year":"2012","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib87","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1152\/japplphysiol.00941.2003","article-title":"Signal transduction by heme-containing PAS-domain proteins","volume":"96","author":"Gilles-Gonzalez","year":"2004","journal-title":"J. Appl. Physiol."},{"issue":"17","key":"10.1016\/j.fct.2019.110822_bib88","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.1016\/S0021-9258(18)68452-2","article-title":"Characterization of a bovine cone photoreceptor phosphodiesterase purified by cyclic GMP-sepharose chromatography","volume":"263","author":"Gillespie","year":"1988","journal-title":"J. Biol. Chem."},{"issue":"1\u20132","key":"10.1016\/j.fct.2019.110822_bib89","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0167-4889(01)00086-6","article-title":"Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain","volume":"1539","author":"Giordano","year":"2001","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib90","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hipo.22128","article-title":"PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model","volume":"23","author":"Giralt","year":"2013","journal-title":"Hippocampus"},{"issue":"20","key":"10.1016\/j.fct.2019.110822_bib91","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","article-title":"Oral sildenafil in the treatment of erectile dysfunction","volume":"338","author":"Goldstein","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.fct.2019.110822_bib92","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1016\/j.bmcl.2013.10.014","article-title":"PDE2 inhibition: potential for the treatment of cognitive disorders","volume":"23","author":"Gomez","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib93","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib94","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1074\/jbc.M511468200","article-title":"cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11","volume":"281","author":"Gross-Langenhoff","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib95","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijcard.2008.04.061","article-title":"Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure","volume":"136","author":"Guazzi","year":"2009","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib96","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jss.2013.08.005","article-title":"Neuroprotective effect of tadalafil, a PDE-5 inhibitor, and its modulation by L-NAME in mouse model of ischemia-reperfusion injury","volume":"186","author":"Gulati","year":"2014","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.fct.2019.110822_bib97","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2016.10.017","article-title":"Phosphodiesterase 10A inhibition attenuates sleep deprivation-induced deficits in long-term fear memory","volume":"635","author":"Guo","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.fct.2019.110822_bib98","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuropharm.2017.01.004","article-title":"FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP\/PS1 transgenic mice via cAMP\/PKA\/CREB signaling and anti-inflammatory effects","volume":"116","author":"Guo","year":"2017","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib99","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0091270005276847","article-title":"The clinical pharmacokinetics of phosphodiesterase\u20105 inhibitors for erectile dysfunction","volume":"45","author":"Gupta","year":"2005","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13311-014-0309-7","article-title":"Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease","volume":"12","author":"Gurney","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib101","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1006\/bbrc.1998.9379","article-title":"Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3\u2032, 5\u2032-cyclic nucleotide phosphodiesterase","volume":"250","author":"Hayashi","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib102","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0006-291X(02)02371-9","article-title":"Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene","volume":"297","author":"Hayashi","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib103","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/1381612820666140826114601","article-title":"Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview","volume":"21","author":"Heckman","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.fct.2019.110822_bib104","series-title":"Phosphodiesterases: CNS Functions and Diseases","first-page":"135","article-title":"From age-related cognitive decline to Alzheimer's disease: a translational overview of the potential role for phosphodiesterases","author":"Heckman","year":"2017"},{"key":"10.1016\/j.fct.2019.110822_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2018.02.007","article-title":"Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: clinical overview and translational considerations","author":"Heckman","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"12","key":"10.1016\/j.fct.2019.110822_bib106","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1038\/npp.2016.106","article-title":"Phosphodiesterase 11A (PDE11A), enriched in ventral hippocampus neurons, is required for consolidation of social but not nonsocial memories in mice","volume":"41","author":"Hegde","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"3\u20134","key":"10.1016\/j.fct.2019.110822_bib107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000338020","article-title":"Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures","volume":"21","author":"Heine","year":"2013","journal-title":"Neurosignals"},{"key":"10.1016\/j.fct.2019.110822_bib108","first-page":"242","article-title":"Selective inhibitiors of three forms of cyclic nucletide phosphodiesterase-Basic and potential clinical applications","volume":"16","author":"Hidaka","year":"1984","journal-title":"Adv. Cyclic Nucleotide Protein Phosphorylation Res."},{"key":"10.1016\/j.fct.2019.110822_bib109","doi-asserted-by":"crossref","DOI":"10.1097\/00004850-199100610-00005","article-title":"Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes","author":"Hindmarch","year":"1991","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib110","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1476-5381.2010.01014.x","article-title":"Cilostazol prevents amyloid \u03b2 peptide25\u201035\u2010induced memory impairment and oxidative stress in mice","volume":"161","author":"Hiramatsu","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.fct.2019.110822_bib111","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejphar.2007.06.045","article-title":"Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain","volume":"573","author":"Hirose","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.fct.2019.110822_bib112","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fnins.2016.00178","article-title":"Alzheimer's disease and hippocampal adult neurogenesis; exploring shared mechanisms","volume":"10","author":"Hollands","year":"2016","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib113","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/17425255.2017.1244265","article-title":"Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors","volume":"13","author":"Hong","year":"2017","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib114","first-page":"639","article-title":"Novel cilostamide analogs, phosphodiesterase 3 inhibitors, produce positive inotropic but differential lusitropic and chronotropic effects on isolated rat atria","volume":"20","author":"Hosseini","year":"2017","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.fct.2019.110822_bib115","series-title":"PDE4 cAMP-specific Phosphodiesterases","author":"Houslay","year":"2001"},{"issue":"22","key":"10.1016\/j.fct.2019.110822_bib116","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","article-title":"Keynote review: phosphodiesterase-4 as a therapeutic target","volume":"10","author":"Houslay","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.fct.2019.110822_bib117","first-page":"407","article-title":"Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction","volume":"38","author":"Huang","year":"2013","journal-title":"PT"},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib118","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cell.2012.02.040","article-title":"Alzheimer mechanisms and therapeutic strategies","volume":"148","author":"Huang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.fct.2019.110822_bib119","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M404338200","article-title":"Molecular determinants of cGMP-binding to chicken cone photoreceptor phosphodiesterase","author":"Huang","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.fct.2019.110822_bib120","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.bcp.2007.03.010","article-title":"L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition","volume":"73","author":"Huang","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.fct.2019.110822_bib121","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/aps.2016.88","article-title":"Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP\/CREB signaling pathway in PC12 cells","volume":"37","author":"Huang","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib122","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12929-017-0355-7","article-title":"Drug candidates in clinical trials for Alzheimer's disease","volume":"24","author":"Hung","year":"2017","journal-title":"J. Biomed. Sci."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib123","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.neuropharm.2011.05.009","volume":"61","author":"Hutson","year":"2011","journal-title":"Neuropharmacology"},{"issue":"02","key":"10.1016\/j.fct.2019.110822_bib124","first-page":"435","article-title":"Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor","volume":"82","author":"Ikeda","year":"1999","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2174\/1381612820666140826113731","article-title":"Phosphodiesterase inhibitors as therapeutics for traumatic brain injury","volume":"21","author":"J Titus","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.fct.2019.110822_bib126","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejphar.2014.10.039","article-title":"Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats","volume":"746","author":"Jabaris","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"36","key":"10.1016\/j.fct.2019.110822_bib127","doi-asserted-by":"crossref","first-page":"60223","DOI":"10.18632\/oncotarget.19428","article-title":"TNF\u03b1 affects CREB-mediated neuroprotective signaling pathways of synaptic plasticity in neurons as revealed by proteomics and phospho-proteomics","volume":"8","author":"Jensen","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.fct.2019.110822_bib128","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00018-005-4533-5","article-title":"Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development","volume":"62","author":"Jeon","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib129","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1017\/S1461145713001533","article-title":"Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP\/PS1 transgenic mice by stimulation of NO\/cGMP signalling","volume":"17","author":"Jin","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1047-8477(02)00502-6","article-title":"Three-dimensional structure of non-activated cGMP phosphodiesterase 6 and comparison of its image with those of activated forms","volume":"139","author":"Kajimura","year":"2002","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.fct.2019.110822_bib131","series-title":"Proceedings of the National Academy of Sciences","first-page":"201000730","article-title":"Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes","author":"Kelly","year":"2010"},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib132","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib133","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1038\/s41598-017-04082-0","article-title":"Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion","volume":"7","author":"Kitamura","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib134","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/ijms18040696","article-title":"Phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair","volume":"18","author":"Knott","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib135","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.110.170191","article-title":"Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect","volume":"334","author":"Koka","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.fct.2019.110822_bib136","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2013.01.031","article-title":"Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia\/reperfusion injury in type 2 diabetic mice","volume":"60","author":"Koka","year":"2013","journal-title":"Free Radic. Biol. Med."},{"issue":"10076","key":"10.1016\/j.fct.2019.110822_bib137","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(16)32381-9","article-title":"Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble","volume":"389","author":"Kontis","year":"2017","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006643","article-title":"Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders","volume":"4","author":"Krahe","year":"2009","journal-title":"PLoS One"},{"issue":"5\u20136","key":"10.1016\/j.fct.2019.110822_bib139","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.neuropharm.2011.12.021","article-title":"Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP","volume":"62","author":"Kroker","year":"2012","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib140","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.neurobiolaging.2014.03.023","article-title":"PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition","volume":"35","author":"Kroker","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib141","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"A review on Alzheimer's disease pathophysiology and its management: an update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.fct.2019.110822_bib142","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.biopha.2017.01.059","article-title":"Inhibitor of phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's type","volume":"88","author":"Kumar","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.fct.2019.110822_bib143","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2014.08.034","article-title":"Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia","volume":"73","author":"Kwon","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib144","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"10.1016\/j.fct.2019.110822_bib145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0006-8993(01)03023-2","article-title":"Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey","volume":"920","author":"Lamontagne","year":"2001","journal-title":"Brain Res."},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib146","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.neurobiolaging.2014.03.027","article-title":"Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology","volume":"35","author":"Laurent","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.fct.2019.110822_bib147","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.brainres.2011.11.007","article-title":"Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity, protects against ischemic brain injury in rats","volume":"1431","author":"Lee","year":"2012","journal-title":"Brain Res."},{"issue":"11","key":"10.1016\/j.fct.2019.110822_bib148","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/jnr.23421","article-title":"Cilostazol suppresses \u03b2\u2010amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1\u2010coupled retinoic acid receptor\u2010\u03b2","volume":"92","author":"Lee","year":"2014","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib149","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1523\/JNEUROSCI.5236-10.2011","article-title":"Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling","volume":"31","author":"Li","year":"2011","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.fct.2019.110822_bib150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145766","article-title":"Phosphodiesterase 5a inhibition with adenoviral short hairpin RNA benefits infarcted heart partially through activation of Akt signaling pathway and reduction of inflammatory cytokines","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib151","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/acs.jmedchem.5b01751","article-title":"Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric diseases","volume":"59","author":"Li","year":"2016","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib152","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0090-4295(02)02439-1","article-title":"Phosphodiesterases as therapeutic targets","volume":"61","author":"Lin","year":"2003","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib153","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1743-6109.2011.02615.x","article-title":"Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature","volume":"9","author":"Lombardi","year":"2012","journal-title":"J. Sex. Med."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib154","article-title":"Nimodipine for primary degenerative, mixed and vascular dementia","author":"Lopez-Arrieta","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-1119(99)00171-7","article-title":"Isolation and characterization of PDE10A, a novel human 3\u2032, 5\u2032-cyclic nucleotide phosphodiesterase","volume":"234","author":"Loughney","year":"1999","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib156","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00213-015-4129-1","article-title":"Cyclic GMP\u2013mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice","volume":"233","author":"Lueptow","year":"2016","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib157","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib158","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acn3.79","article-title":"Phosphodiesterase III inhibitor promotes drainage of cerebrovascular \u03b2\u2010amyloid","volume":"1","author":"Maki","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib159","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/S0021-9258(19)68134-2","article-title":"Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues","volume":"257","author":"Martins","year":"1982","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib160","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ejhf.711","article-title":"Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase\u20105A inhibitor vardenafil in rats with type 2 diabetes","volume":"19","author":"M\u00e1ty\u00e1s","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib161","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/mol.64.3.533","article-title":"Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system","volume":"64","author":"Maurice","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib162","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib163","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/archneur.64.3.456","article-title":"Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease","volume":"64","author":"McLachlan","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.fct.2019.110822_bib164","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnins.2011.00021","article-title":"Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions","volume":"5","author":"Medina","year":"2011","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib165","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1523\/JNEUROSCI.4177-05.2006","article-title":"Restoration of neuronal plasticity by a phosphodiesterase type 1 inhibitor in a model of fetal alcohol exposure","volume":"26","author":"Medina","year":"2006","journal-title":"J. Neurosci."},{"issue":"18","key":"10.1016\/j.fct.2019.110822_bib166","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s00018-013-1340-2","article-title":"Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival","volume":"70","author":"Medina-Rodr\u00edguez","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib167","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1043-2760(01)00523-9","article-title":"Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling","volume":"13","author":"Mehats","year":"2002","journal-title":"Trends Endocrinol. Metab."},{"issue":"19","key":"10.1016\/j.fct.2019.110822_bib168","doi-asserted-by":"crossref","first-page":"8549","DOI":"10.1021\/jm301189c","article-title":"Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design","volume":"55","author":"Meng","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib169","first-page":"54","article-title":"Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia","volume":"8","author":"Menniti","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00002093-200301000-00006","article-title":"The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review","volume":"17","author":"Michael","year":"2003","journal-title":"Alzheimers Dis. Assoc. Disord."},{"issue":"11","key":"10.1016\/j.fct.2019.110822_bib171","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1248\/cpb.c17-00564","volume":"65","author":"Mikami","year":"2017","journal-title":"Chem. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib172","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/frne.1994.1012","article-title":"The area postrema and vomiting","volume":"15","author":"Miller","year":"1994","journal-title":"Front. Neuroendocrinol."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib173","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neuropharm.2003.09.009","article-title":"Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia","volume":"46","author":"Mizuno","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.fct.2019.110822_bib174","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.resp.2018.01.008","article-title":"Inhibitors of phosphodiesterases in the treatment of cough","author":"Mokry","year":"2018","journal-title":"Respir. Physiol. Neurobiol."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0014-2999(92)90602-Z","article-title":"Effect of different subtypes of cognition enhancers on long-term potentiation in the rat dentate gyrus in vivo","volume":"215","author":"Moln\u00e1r","year":"1992","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib176","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/stem.2480","article-title":"Phosphodiesterase7 inhibition activates adult neurogenesis in hippocampus and subventricular zone in vitro and in vivo","volume":"35","author":"MoralesGarcia","year":"2017","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib177","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchemneu.2010.03.004","article-title":"The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D","volume":"40","author":"Mori","year":"2010","journal-title":"J. Chem. Neuroanat."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib178","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1471-4159.2001.00407.x","article-title":"Expression and role of phosphodiesterase 6 in the chicken pineal gland","volume":"78","author":"Morin","year":"2001","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib179","first-page":"10","article-title":"Functions of PDE3 isoforms in cardiac muscle","volume":"5","author":"Movsesian","year":"2018","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.fct.2019.110822_bib180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0165-6147(91)90484-A","article-title":"Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes","volume":"12","author":"Nicholson","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib181","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1074\/jbc.C400505200","article-title":"Real-time monitoring of the PDE2 activity of live cells hormone-stimulated camp hydrolysis is faster than hormone-stimulated camp synthesis","volume":"280","author":"Nikolaev","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.fct.2019.110822_bib182","series-title":"Arterial Chemoreception","first-page":"287","article-title":"Effect of oxygen on phosphodiesterases (PDE) 3 and 4 isoforms and PKA activity in the superior cervical ganglia","author":"Nunes","year":"2012"},{"key":"10.1016\/j.fct.2019.110822_bib183","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fnagi.2017.00337","article-title":"Cilostazol suppresses a\u03b2-induced neurotoxicity in SH-SY5Y cells through inhibition of oxidative stress and MAPK signaling pathway","volume":"9","author":"Oguchi","year":"2017","journal-title":"Front. Aging Neurosci."},{"issue":"49","key":"10.1016\/j.fct.2019.110822_bib184","doi-asserted-by":"crossref","first-page":"16419","DOI":"10.1523\/JNEUROSCI.3317-10.2010","article-title":"Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits","volume":"30","author":"Oliveira","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.fct.2019.110822_bib185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cellsig.2017.06.015","article-title":"Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: a systematic review of preclinical studies","volume":"38","author":"\u00d6lmestig","year":"2017","journal-title":"Cell. Signal."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib186","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.exger.2013.03.001","article-title":"Implication of JNK pathway on tau pathology and cognitive decline in a senescence-accelerated mouse model","volume":"48","author":"Orejana","year":"2013","journal-title":"Exp. Gerontol."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib187","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/gerona\/glu106","article-title":"Sildenafil decreases BACE1 and cathepsin B levels and reduces APP amyloidogenic processing in the SAMP8 mouse","volume":"70","author":"Orejana","year":"2014","journal-title":"J. Gerontol. Ser. A: Biomed. Sci. Med. Sci."},{"key":"10.1016\/j.fct.2019.110822_bib188","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.physbeh.2015.07.030","article-title":"Protective effect of exercise and sildenafil on acute stress and cognitive function","volume":"151","author":"Ozbeyli","year":"2015","journal-title":"Physiol. Behav."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib189","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2011.04.068","article-title":"Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid \u03b2-induced cognitive deficits associated with decreased amyloid \u03b2 accumulation","volume":"408","author":"Park","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5534\/wjmh.2014.32.1.18","article-title":"Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature","volume":"32","author":"Park","year":"2014","journal-title":"World J. Mens Health"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib191","first-page":"394","article-title":"Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. The Nimodipine Study Group","volume":"15","author":"Parnetti","year":"1993","journal-title":"Clin. Ther."},{"key":"10.1016\/j.fct.2019.110822_bib192","first-page":"2015","article-title":"Phosphodiesterase-5 inhibitors: action on the signaling pathways of neuroinflammation, neurodegeneration, and cognition","author":"Peixoto","year":"2015","journal-title":"Mediat. Inflamm."},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib193","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.neurobiolaging.2013.03.011","article-title":"Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease","volume":"34","author":"Perez-Gonzalez","year":"2013","journal-title":"Neurobiol. Aging"},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib194","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.neurobiolaging.2013.03.011","article-title":"Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease","volume":"34","author":"Perez-Gonzalez","year":"2013","journal-title":"Neurobiol. Aging"},{"issue":"3\u20134","key":"10.1016\/j.fct.2019.110822_bib195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0891-0618(00)00097-1","article-title":"Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H] rolipram binding autoradiography: comparison with monkey and rat brain","volume":"20","author":"P\u00e9rez-Torres","year":"2000","journal-title":"J. Chem. Neuroanat."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib196","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0014-4886(03)00042-6","article-title":"Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization","volume":"182","author":"P\u00e9rez-Torres","year":"2003","journal-title":"Exp. Neurol."},{"issue":"13","key":"10.1016\/j.fct.2019.110822_bib197","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1038\/npp.2014.154","article-title":"The PDE4 inhibitor HT-0712 improves hippocampus-dependent memory in aged mice","volume":"39","author":"Peters","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib198","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1523\/JNEUROSCI.14-03-01251.1994","article-title":"Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation","volume":"14","author":"Polli","year":"1994","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib199","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.neuint.2004.03.022","article-title":"Phosphodiesterase type 5 inhibition improves early memory consolidation of object information","volume":"45","author":"Prickaerts","year":"2004","journal-title":"Neurochem. Int."},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib200","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib201","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nbd.2010.01.013","article-title":"Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF","volume":"38","author":"Puerta","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"25","key":"10.1016\/j.fct.2019.110822_bib202","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","article-title":"Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-\u03b2 load in an Alzheimer's disease mouse model","volume":"29","author":"Puzzo","year":"2009","journal-title":"J. Neurosci."},{"issue":"18","key":"10.1016\/j.fct.2019.110822_bib203","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1523\/JNEUROSCI.5463-11.2012","article-title":"CREB-dependent transcriptional control and quantal changes in persistent long-term potentiation in hippocampal interneurons","volume":"32","author":"Ran","year":"2012","journal-title":"J. Neurosci."},{"issue":"16","key":"10.1016\/j.fct.2019.110822_bib204","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1007\/s00213-014-3492-7","article-title":"In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia","volume":"231","author":"Redrobe","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.fct.2019.110822_bib205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2015.04.040","article-title":"Characterisation of Lu AF33241: a novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A","volume":"761","author":"Redrobe","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.fct.2019.110822_bib206","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","article-title":"Selective phosphodiesterase inhibitors: a promising target for cognition enhancement","volume":"202","author":"Reneerkens","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.fct.2019.110822_bib207","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","article-title":"Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801","volume":"236","author":"Reneerkens","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib208","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0006-291X(03)00021-4","article-title":"Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene","volume":"301","author":"Rentero","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.fct.2019.110822_bib209","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1111\/j.1460-9568.2007.05589.x","article-title":"Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains","volume":"25","author":"ReyesIrisarri","year":"2007","journal-title":"Eur. J. Neurosci."},{"issue":"12","key":"10.1016\/j.fct.2019.110822_bib210","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2174\/0929867323666160428110059","article-title":"New therapeutic applications of phosphodiesterase 5 inhibitors (PDE5-Is)","volume":"23","author":"Ribaudo","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.fct.2019.110822_bib211","doi-asserted-by":"crossref","first-page":"46320","DOI":"10.1038\/srep46320","article-title":"Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease","volume":"7","author":"Ricciarelli","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib212","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0968-0004(03)00172-5","article-title":"Phototransduction: crystal clear","volume":"28","author":"Ridge","year":"2003","journal-title":"Trends Biochem. Sci."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib213","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0028-3908(98)00190-7","article-title":"Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret","volume":"38","author":"Robichaud","year":"1999","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib214","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0028-3908(00)00142-8","article-title":"PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway","volume":"40","author":"Robichaud","year":"2001","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.fct.2019.110822_bib215","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI0215506","article-title":"Deletion of phosphodiesterase 4D in mice shortens \u03b1 2-adrenoceptor\u2013mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib216","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","article-title":"PDE10A inhibition reverses subchronic PCP\u2010induced deficits in attentional set\u2010shifting in rats","volume":"21","author":"Rodefer","year":"2005","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib217","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.neuropharm.2011.08.008","article-title":"Selective phosphodiesterase inhibitors improve performance on the ED\/ID cognitive task in rats","volume":"62","author":"Rodefer","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.fct.2019.110822_bib218","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fnbeh.2014.00091","article-title":"A phosphodiesterase 4-controlled switch between memory extinction and strengthening in the hippocampus","volume":"8","author":"Roesler","year":"2014","journal-title":"Front. Behav. Neurosci."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib219","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.neurobiolaging.2015.04.014","article-title":"CREB expression mediates amyloid \u03b2-induced basal BDNF downregulation","volume":"36","author":"Rosa","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib220","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2004.10.002","article-title":"Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk","volume":"47","author":"Rosano","year":"2005","journal-title":"Eur. Urol."},{"key":"10.1016\/j.fct.2019.110822_bib221","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0007-0971(83)90009-8","article-title":"Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948)","volume":"77","author":"Rudd","year":"1983","journal-title":"Br. J. Dis. Chest"},{"issue":"1\u20133","key":"10.1016\/j.fct.2019.110822_bib222","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2006.11.041","article-title":"Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors","volume":"558","author":"Rutten","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib223","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/npp.2009.24","article-title":"Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats","volume":"34","author":"Rutten","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib224","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/jpet.114.214155","article-title":"GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species","volume":"350","author":"Rutter","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib225","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1471-4159.2004.02354.x","article-title":"Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP\/cyclic AMP\u2010dependent protein kinase\/cyclic AMP\u2010response element binding protein pathway in primary striatal neurons","volume":"89","author":"Sasaki","year":"2004","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib226","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clinthera.2017.01.001","article-title":"Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: pharmacology and clinical impact of the sildenafil citrate orodispersible tablet formulation","volume":"39","author":"Scaglione","year":"2017","journal-title":"Clin. Ther."},{"issue":"20","key":"10.1016\/j.fct.2019.110822_bib227","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1021\/bi049868i","article-title":"Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity","volume":"43","author":"Scapin","year":"2004","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib228","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF00172808","article-title":"Stereoselective inhibition of calmodulin-dependent cAMP phosphodiesterase from bovine heart by (+)-and (\u2212)-nimodipine","volume":"335","author":"Sch\u00e4chtele","year":"1987","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib229","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00702-005-0301-9","article-title":"Inhibition of phospholipase A 2 activity reduces membrane fluidity in rat hippocampus","volume":"112","author":"Schaeffer","year":"2005","journal-title":"J. Neural Transm."},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib230","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib231","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.fct.2019.110822_bib232","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182019","article-title":"The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease","volume":"12","author":"Schwenkgrub","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib233","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00002093-200301000-00006","article-title":"The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review","volume":"17","author":"Sha","year":"2003","journal-title":"Alzheimers Dis. Assoc. Disord."},{"key":"10.1016\/j.fct.2019.110822_bib234","series-title":"Regulation and Function of the Cyclic Nucleotide Phosphodiesterase (PDE3) Gene Family","author":"Shakur","year":"2000"},{"issue":"24","key":"10.1016\/j.fct.2019.110822_bib235","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1021\/jm500836h","article-title":"Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent","volume":"57","author":"Shao","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.fct.2019.110822_bib236","doi-asserted-by":"crossref","first-page":"F671","DOI":"10.1152\/ajprenal.00042.2016","article-title":"The role of cGMP and its signaling pathways in kidney disease","volume":"311","author":"Shen","year":"2016","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.fct.2019.110822_bib237","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7464872","article-title":"Icariin attenuates synaptic and cognitive deficits in an a\u03b21\u201342-induced rat model of Alzheimer's disease","author":"Sheng","year":"2017","journal-title":"BioMed Res. Int."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib238","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ijir.2013.38","article-title":"Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study","volume":"26","author":"Shim","year":"2014","journal-title":"Int. J. Impot. Res."},{"issue":"16","key":"10.1016\/j.fct.2019.110822_bib239","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.1523\/JNEUROSCI.23-16-06452.2003","article-title":"Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation","volume":"23","author":"Shimizu-Albergine","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.fct.2019.110822_bib240","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2012.06.048","article-title":"Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe\/PS1dE9 mouse model of Alzheimer's disease","volume":"64","author":"Sierksma","year":"2013","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib241","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib242","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/mol.104.002246","article-title":"Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes","volume":"66","author":"Smith","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib243","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1538-7836.2011.04576.x","article-title":"Novel roles of cAMP\/cGMP\u2010dependent signaling in platelets","volume":"10","author":"Smolenski","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"17","key":"10.1016\/j.fct.2019.110822_bib244","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1007\/s00213-016-4346-2","article-title":"Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats","volume":"233","author":"Snyder","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.fct.2019.110822_bib245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuroscience.2016.03.062","article-title":"Rolipram improves cognition, reduces anxiety-and despair-like behaviors and impacts hippocampal neuroplasticity after transient global cerebral ischemia","volume":"326","author":"Soares","year":"2016","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib246","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0955-0674(99)00073-3","article-title":"Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions","volume":"12","author":"Soderling","year":"2000","journal-title":"Curr. Opin. Cell Biol."},{"issue":"15","key":"10.1016\/j.fct.2019.110822_bib247","doi-asserted-by":"crossref","first-page":"8991","DOI":"10.1073\/pnas.95.15.8991","article-title":"Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase","volume":"95","author":"Soderling","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"25","key":"10.1016\/j.fct.2019.110822_bib248","doi-asserted-by":"crossref","first-page":"15553","DOI":"10.1074\/jbc.273.25.15553","article-title":"Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases","volume":"273","author":"Soderling","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.fct.2019.110822_bib249","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib250","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1476-5381.1996.tb15450.x","article-title":"Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF\u03b1 generation from human monocytes by interacting with a \u2018low\u2010affinity\u2019phosphodiesterase 4 conformer","volume":"118","author":"Souness","year":"1996","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib251","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00120-017-0341-4","article-title":"Side effects of erectile dysfunction drug treatment","volume":"56","author":"Sperling","year":"2017","journal-title":"Urol. Ausg. A"},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib252","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.coph.2004.12.008","article-title":"Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides","volume":"5","author":"Steiner","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.fct.2019.110822_bib253","doi-asserted-by":"crossref","first-page":"21826","DOI":"10.1038\/srep21826","article-title":"Discovery of novel PDE9 inhibitors capable of inhibiting A\u03b2 aggregation as potential candidates for the treatment of Alzheimer's disease","volume":"6","author":"Su","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.fct.2019.110822_bib254","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fphys.2014.00501","article-title":"Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP-and NO-dependent mechanisms in the insulin-mediated platelet aggregation","volume":"5","author":"Suslova","year":"2015","journal-title":"Front. Physiol."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib255","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0021-9258(19)77423-7","article-title":"Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles","volume":"232","author":"Sutherland","year":"1958","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.fct.2019.110822_bib256","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1523\/JNEUROSCI.3257-10.2011","article-title":"Upregulation of CREB-mediated transcription enhances both short-and long-term memory","volume":"31","author":"Suzuki","year":"2011","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib257","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/psyg.12021","article-title":"Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis","volume":"13","author":"Taguchi","year":"2013","journal-title":"Psychogeriatrics"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib258","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nm1175","article-title":"Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy","volume":"11","author":"Takimoto","year":"2005","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib259","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain\u2014implications for Alzheimer disease","volume":"11","author":"Tarasoff-Conway","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib260","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1006\/jmbi.2001.4813","article-title":"Molecular organization of bovine rod cGMP-phosphodiesterase 61","volume":"310","author":"Tcheudji","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib261","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13311-014-0327-5","article-title":"Synaptic therapy in Alzheimer's disease: a CREB-centric approach","volume":"12","author":"Teich","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"1\u20132","key":"10.1016\/j.fct.2019.110822_bib262","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jns.2014.09.012","article-title":"Clinical and demographic predictors of mild cognitive impairment for converting to Alzheimer's disease and reverting to normal cognition","volume":"346","author":"Tokuchi","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib263","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1080\/10641960802580232","article-title":"Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies","volume":"30","author":"Tomassoni","year":"2008","journal-title":"Clin. Exp. Hypertens."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib264","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/pupt.1999.0181","article-title":"ArifloTM (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic","volume":"12","author":"Torphy","year":"1999","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.fct.2019.110822_bib265","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1055\/s-0032-1321861","article-title":"Regulation of adrenal steroidogenesis by the high-affinity phosphodiesterase 8 family","volume":"44","author":"Tsai","year":"2012","journal-title":"Horm. Metab. Res."},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib266","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuropharm.2008.07.005","article-title":"The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents","volume":"55","author":"Van Der Staay","year":"2008","journal-title":"Neuropharmacology"},{"issue":"8\u20139","key":"10.1016\/j.fct.2019.110822_bib267","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1025704031210","article-title":"Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain","volume":"31","author":"Van Staveren","year":"2002","journal-title":"J. Neurocytol."},{"issue":"8","key":"10.1016\/j.fct.2019.110822_bib268","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/j.0953-816X.2004.03327.x","article-title":"Species differences in the localization of cGMP\u2010producing and NO\u2010responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry","volume":"19","author":"Van Staveren","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.fct.2019.110822_bib269","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2016.01.031","article-title":"The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses","volume":"303","author":"Vanmierlo","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.fct.2019.110822_bib270","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuint.2018.12.015","article-title":"Sildenafil treatment of vascular dementia in aged rats","volume":"127","author":"Venkat","year":"2019","journal-title":"Neurochem. Int."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib271","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0149-7634(99)00037-8","article-title":"The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?","volume":"23","author":"Wadenberg","year":"1999","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.fct.2019.110822_bib272","doi-asserted-by":"crossref","DOI":"10.1124\/mol.104.009423","article-title":"Identification and characterisation of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cyclic AMP phosphodiesterase gene","author":"Wallace","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib273","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-1119(01)00783-1","article-title":"Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution","volume":"280","author":"Wang","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.fct.2019.110822_bib274","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0378-1119(03)00733-9","article-title":"Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5): differential tissue distribution and subcellular localization of PDE9A variants","volume":"314","author":"Wang","year":"2003","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib275","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1017\/S1461145711000836","article-title":"The phosphodiesterase-4 inhibitor rolipram reverses A\u03b2-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats","volume":"15","author":"Wang","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.fct.2019.110822_bib276","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pbb.2014.07.006","article-title":"Pretreatment with antiasthmatic drug ibudilast ameliorates A\u03b21\u201342-induced memory impairment and neurotoxicity in mice","volume":"124","author":"Wang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib277","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/1381612820666140826115559","article-title":"Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases","volume":"21","author":"Wang","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"issue":"14","key":"10.1016\/j.fct.2019.110822_bib278","doi-asserted-by":"crossref","first-page":"17380","DOI":"10.18632\/oncotarget.8041","article-title":"The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.fct.2019.110822_bib279","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","article-title":"A systemic view of Alzheimer disease\u2014insights from amyloid-\u03b2 metabolism beyond the brain","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib280","doi-asserted-by":"crossref","first-page":"12044","DOI":"10.1038\/s41598-017-08070-2","article-title":"Inhibition of PDE2 reverses beta amyloid induced memory impairment through regulation of PKA\/PKG-dependent neuro-inflammatory and apoptotic pathways","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib281","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1161\/01.STR.0000221783.08037.a9","article-title":"Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion","volume":"37","author":"Watanabe","year":"2006","journal-title":"Stroke"},{"issue":"13","key":"10.1016\/j.fct.2019.110822_bib282","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1021\/acs.jmedchem.7b01370","article-title":"Novel phosphodiesterase inhibitors for cognitive improvement in Alzheimer's disease: miniperspective","volume":"61","author":"Wu","year":"2018","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib283","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.neurobiolaging.2014.08.028","article-title":"Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress","volume":"36","author":"Xu","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib284","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.sxmr.2017.08.001","article-title":"Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction","volume":"6","author":"Yafi","year":"2018","journal-title":"Sex. Med. Rev."},{"issue":"6","key":"10.1016\/j.fct.2019.110822_bib285","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/jsm.12499","article-title":"The efficacy of PDE 5 inhibitors alone or in combination with alpha\u2010blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta\u2010analysis","volume":"11","author":"Yan","year":"2014","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.fct.2019.110822_bib286","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fphar.2017.00106","article-title":"Icariside II effectively reduces spatial learning and memory impairments in Alzheimer's disease model mice targeting beta-amyloid production","volume":"8","author":"Yan","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"13","key":"10.1016\/j.fct.2019.110822_bib287","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1007\/s00213-014-3442-4","article-title":"Cilostazol improves hippocampus-dependent long-term memory in mice","volume":"231","author":"Yanai","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.fct.2019.110822_bib288","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neuropharm.2016.12.006","article-title":"Long-term cilostazol administration ameliorates memory decline in senescence-accelerated mouse prone 8 (SAMP8) through a dual effect on cAMP and blood-brain barrier","volume":"116","author":"Yanai","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.fct.2019.110822_bib289","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2017.11.008","article-title":"Long-term cilostazol administration prevents age-related decline of hippocampus-dependent memory in mice","volume":"129","author":"Yanai","year":"2018","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib290","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1271\/bbb.67.973","article-title":"cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles","volume":"67","author":"Yanaka","year":"2003","journal-title":"Biosci. Biotechnol. Biochem."},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib291","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur. Urol."},{"issue":"16","key":"10.1016\/j.fct.2019.110822_bib292","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1046\/j.1432-1327.2001.02366.x","article-title":"Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A) Comparison of rat and human PDE11A splicing variants","volume":"268","author":"Yuasa","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"11","key":"10.1016\/j.fct.2019.110822_bib293","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCRESAHA.106.144501","article-title":"cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology","volume":"100","author":"Zaccolo","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.fct.2019.110822_bib294","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainres.2011.08.036","article-title":"Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice","volume":"1417","author":"Zeitlin","year":"2011","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.fct.2019.110822_bib295","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4103\/1008-682X.167721","article-title":"Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update","volume":"18","author":"Zhang","year":"2016","journal-title":"Asian J. Androl."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib296","first-page":"587","article-title":"Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme","volume":"27","author":"Zhang","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.fct.2019.110822_bib297","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1161\/01.STR.0000034399.95249.59","article-title":"Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats","volume":"33","author":"Zhang","year":"2002","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.fct.2019.110822_bib298","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.molcel.2004.07.005","article-title":"A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases","volume":"15","author":"Zhang","year":"2004","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib299","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainres.2006.08.028","article-title":"Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke","volume":"1118","author":"Zhang","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.fct.2019.110822_bib300","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbr.2013.05.017","article-title":"Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP\/PS1 transgenic mice","volume":"250","author":"Zhang","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib301","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/1381612820666140826115245","article-title":"The roles of phosphodiesterase 2 in the central nervous and peripheral systems","volume":"21","author":"Zhang","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.fct.2019.110822_bib302","doi-asserted-by":"crossref","first-page":"40115","DOI":"10.1038\/srep40115","article-title":"Comparison of the pharmacological profiles of selective PDE4B and PDE4D inhibitors in the central nervous system","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.fct.2019.110822_bib303","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/14756366.2017.1412315","article-title":"Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.fct.2019.110822_bib304","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mad.2015.07.002","article-title":"A novel phosphodiesterase-5 Inhibitor: yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP\/PS1 transgenic mice model","volume":"150","author":"Zhu","year":"2015","journal-title":"Mech. Ageing Dev."},{"issue":"3","key":"10.1016\/j.fct.2019.110822_bib305","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijcard.2014.01.102","article-title":"PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials","volume":"172","author":"Zhuang","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.fct.2019.110822_bib306","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s11011-016-9814-1","article-title":"Inhibition of phosphodiesterase-4 reverses the cognitive dysfunction and oxidative stress induced by A\u03b225\u201335 in rats","volume":"31","author":"Zhuo","year":"2016","journal-title":"Metab. Brain Dis."},{"issue":"12","key":"10.1016\/j.fct.2019.110822_bib307","doi-asserted-by":"crossref","first-page":"12051","DOI":"10.1074\/jbc.M413611200","article-title":"Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation","volume":"280","author":"Zoraghi","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.fct.2019.110822_bib308","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/17512433.2016.1212655","article-title":"Avanafil for the treatment of erectile dysfunction","volume":"9","author":"Zurawin","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."}],"container-title":["Food and Chemical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027869151930612X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027869151930612X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:54:30Z","timestamp":1759528470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027869151930612X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":308,"alternative-id":["S027869151930612X"],"URL":"https:\/\/doi.org\/10.1016\/j.fct.2019.110822","relation":{},"ISSN":["0278-6915"],"issn-type":[{"value":"0278-6915","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphodiesterase inhibitors say NO to Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Food and Chemical Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fct.2019.110822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110822"}}